Treatment of essential hypertension in adults.
Treatment of hypertension in children and adolescents from 6 to less than 18 years of age.

Posology
Adults
The recommended starting dose of olmesartan medoxomil is 10 mg once daily. In patients whose blood
pressure is not adequately controlled at this dose, the dose of olmesartan medoxomil may be increased
to 20 mg once daily as the optimal dose. If additional blood pressure reduction is required, olmesartan
medoxomil dose may be increased to a maximum of 40 mg daily or hydrochlorothiazide therapy may be
added.

The antihypertensive effect of olmesartan medoxomil is substantially present within 2 weeks of
initiating therapy and is maximal by about 8 weeks after initiating therapy. This should be borne in
mind when considering changing the dose regimen for any patient.
Elderly (65 years or over)
No adjustment of dosage is generally required in elderly people (see below for dose recommendations
in patients with renal impairment). If up-titration to the maximum dose of 40 mg daily is required,
blood pressure should be closely monitored.
Renal impairment
The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20 – 60
mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in
this patient group. The use of olmesartan medoxomil in patients with severe renal impairment
(creatinine clearance < 20 mL/min) is not recommended, since there is only limited experience in this
patient group (see sections 4.4, 5.2).
Hepatic impairment
No adjustment of dosage recommendations is required for patients with mild hepatic impairment. In
patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily
is recommended and the maximum dose should not exceed 20 mg once daily. Close monitoring of
blood pressure and renal function is advised in hepatically-impaired patients who are already receiving
diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in
patients with severe hepatic impairment, therefore use is not recommended in this patient group (see
sections 4.4 and 5.2). Olmesartan medoxomil should not be used in patients with biliary obstruction (see
section 4.3).
Paediatric population
Children and adolescents from 6 to less than 18 years of age:
The recommended starting dose of olmesartan medoxomil in children from 6 to less than 18 years of
age is 10 mg olmesartan medoxomil once daily. In children whose blood pressure is not adequately
controlled at this dose, the dose of olmesartan medoxomil may be increased to 20 mg once daily. If
additional blood pressure reduction is required, in children who weigh ≥ 35 kg, the olmesartan
medoxomil dose may be increased to a maximum of 40 mg. In children who weigh < 35 kg, the daily
dose should not exceed 20 mg. Other paediatric population:

The safety and efficacy of olmesartan medoxomil in children aged 1 to 5 years old have not yet been
established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a
posology can be made.
Olmesartan medoxomil should not be used in children below 1 years of age because of safety concerns
and lack of data in this age group.
Method of administration
In order to assist compliance, it is recommended that Olmesartan tablets be taken at about the same time
each day, with or without food, for example at breakfast time. The tablet should be swallowed with a
sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed.

USE Intravascular volume depletion:
Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or
sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such
conditions should be corrected before the administration of olmesartan medoxomil.
Other conditions with stimulation of the renin-angiotensin-aldosterone system:
In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-
aldosterone system (e.g. patients with severe congestive heart failure or underlying renal
disease, including renal artery stenosis), treatment with other drugs that affect this system has been
associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. The possibility of
similar effects cannot be excluded with angiotensin II receptor antagonists.

Renovascular hypertension:
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral
renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal
products that affect the renin-angiotensin-aldosterone system.
Renal impairment and kidney transplantation:
When olmesartan medoxomil is used in patients with impaired renal function, periodic monitoring of
serum potassium and creatinine levels is recommended. Use of olmesartan medoxomil is not
recommended in patients with severe renal impairment (creatinine clearance < 20 mL/min) (see
sections 4.2, 5.2). There is no experience of the administration of olmesartan medoxomil in patients
with a recent kidney transplant or in patients with end-stage renal impairment (i.e. creatinine clearance
<12 mL/min).
Hepatic impairment:
There is no experience in patients with severe hepatic impairment and therefore use of olmesartan
medoxomil in this patient group is not recommended (see section 4.2 for dosage recommendations in
patients with mild or moderate hepatic impairment).
Hyperkalaemia:
The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause
hyperkalaemia.
The risk, that may be fatal, is increased in elderly people, in patients with renal insufficiency and in
diabetic patients, in patients concomitantly treated with other medicinal products that may increase
potassium levels, and/or in patients with intercurrent events.
Before considering the concomitant use of medicinal products that affect the renin-angiotensinaldosterone
system, the benefit risk ratio should be evaluated and other alternatives considered (see also
below section “Dual blockade of the renin-angiotensin-aldosterone system (RAAS)”).
The main risk factors for hyperkalaemia to be considered are:
- Diabetes, renal impairment, age (> 70 years)
- Combination with one or more other medicinal products that affect the renin-angiotensin- aldosterone
system and/or potassium supplements. Some medicinal products or therapeutic class of medicinal
products may provoke a hyperkalaemia: salt substitutes containing potassium, potassium-sparing
diuretics, ACE inhibitors, angiotensin II receptors antagonists, non steroidal anti-inflammatory drugs (including
selective COX-2 inhibitors), heparin, immunosuppressor as ciclosporin or tacrolimus, trimethoprim.
- Intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis,
worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular
lysis (e.g, acute limb ischemia, rhabdomyolysis, extended trauma).
Close-monitoring of serum potassium in at risk patients is recommended (see section 4.5).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS):
There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or
aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including
acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin
II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).
If dual blockade therapy is considered absolutely necessary, this should only occur under specialist
supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.
ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with
diabetic nephropathy.
Lithium:
As with other angiotensin-II receptor antagonists, the combination of lithium and olmesartan
medoxomil is not recommended (see section 4.5).
Aortic or mitral valve stenosis; obstructive hypertrophic cardiomyopathy:
As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral valve
stenosis, or obstructive hypertrophic cardiomyopathy.
Primary aldosteronism:
Patients with primary aldosteronism generally will not respond to antihypertensive drugs acting
through inhibition of the renin-angiotensin system. Therefore, the use of Olmesartan medoxomil is not
recommended in such patients.
Sprue-like enteropathy:
In very rare cases severe, chronic diarrhoea with substantial weight loss has been reported in patients
taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed
hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a
patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent
etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If
diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. a gastroenterologist)
advice should be considered.
Ethnic differences:
As with all other angiotensin II antagonists, the blood pressure lowering effect of Olmesartan
medoxomil is somewhat less in black patients than in non-black patients, possibly because of a higher
prevalence of low-renin status in the black hypertensive population.
Pregnancy:
Angiotensin II antagonists should not be initiated during pregnancy. Unless continued angiotensin II
antagonists therapy is considered essential, patients planning pregnancy should be changed to
alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
When pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped
immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Other:
As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart
disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance,
the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Effects of other medicinal products on olmesartan medoxomil:
Other antihypertensive medications:
The blood pressure lowering effect of olmesartan medoxomil can be increased by concomitant use of other
antihypertensive medications.
ACE-inhibitors, angiotensin II receptor blockers or aliskiren:
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS)
through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal
function (including acute renal failure) compared to the use of a single RAAS-acting agent (see
sections 4.3, 4.4 and 5.1).
Potassium supplements and potassium sparing diuretics:
Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant
use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other
drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum
potassium (see section 4.4). Such concomitant use is therefore not recommended.
Non-steroidal anti-inflammatory drugs (NSAIDs):
NSAIDs (including acetylsalicylic acid at doses > 3g/day and also COX-2 inhibitors) and angiotensin-
II receptor antagonists may act synergistically by decreasing glomerular filtration. The risk of the
concomitant use of NSAIDs and angiotensin II antagonists is the occurrence of acute renal failure.
Monitoring of renal function at the beginning of treatment should be recommended as well as regular
hydration of the patient.
Additionally, concomitant treatment can reduce the antihypertensive effect of angiotensin II receptor
antagonists, leading to their partial loss of efficacy.
Bile acid sequestering agent colesevelam:
Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the
systemic exposure and peak plasma concentration of olmesartan and reduces t1/2. Administration of
olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug
interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam
hydrochloride dose should be considered (see section 5.2).
Other compounds:
After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability
of olmesartan was observed. Coadministration of warfarin and digoxin had no effect on the
pharmacokinetics of olmesartan.

Effects of olmesartan medoxomil on other medicinal products:
Lithium:
Reversible increases in serum lithium concentrations and toxicity have been reported during
concomitant administration of lithium with angiotensin converting enzyme inhibitors and angiotensin II
antagonists. Therefore use of olmesartan medoxomil and lithium in combination is not recommended
(see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels
is recommended. Other compounds:
Compounds which have been investigated in specific clinical studies in healthy volunteers include
warfarin, digoxin, an antacid (magnesium aluminium hydroxide), hydrochlorothiazide and pravastatin.
No clinically relevant interactions were observed and in particular olmesartan medoxomil had no
significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics
of digoxin.
Olmesartan had no clinically relevant inhibitory effects on in vitro human cytochrome P450 enzymes
1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4, and had no or minimal inducing effects on rat
cytochrome P450 activities. Therefore in vivo interaction studies with known cytochrome P450
enzyme inhibitors and inducers were not conducted, and no clinically relevant interactions between
olmesartan and drugs metabolised by the above cytochrome P450 enzymes are expected.
Paediatric population:
Interaction studies have only been performed in adults.
It is not known if the interactions in children are similar to those in adults.

Pregnancy

The use of angiotensin II antagonists is not recommended during the first trimester of pregnancy (see
section 4.4). The use of angiotensin II antagonists is contra-indicated during the 2nd and 3rd trimester of
pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors
during the first trimester of pregnancy has not been conclusive; however a small increase in risk
cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II
antagonists,

similar risks may exist for this class of drugs. Unless continued angiotensin receptor blocker therapy
is considered essential, patients planning pregnancy should be changed to alternative antihypertensive
treatments which have an established safety profile for use in pregnancy. When
pregnancy is diagnosed, treatment with angiotensin II antagonists should be stopped immediately,
and, if appropriate, alternative therapy should be started.
Angiotensin II antagonists therapy exposure during the second and third trimesters is known to induce
human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and
neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 “Preclinical Safety Data”.)
Should exposure to angiotensin II antagonists have occurred from the second trimester of pregnancy,
ultrasound check of renal function and skull is recommended. Infants whose mothers have taken
angiotensin II antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).
Breast-feeding
Olmesartan is excreted in the milk of lactating rats but it is not known whether olmesartan is excreted
in human milk. Because no information is available regarding the use of Olmesartan during breastfeeding,
Olmesartan is not recommended and alternative treatments with better established safety
profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Olmesartan has minor or moderate influence on the ability to drive and use machines. Dizziness or
fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the
ability to react.

Summary of the safety profile:

The most commonly reported adverse reactions during treatment with Olmesartan are headache (7.7%), influenza-like symptoms (4.0%) and dizziness (3.7%).

In placebo-controlled monotherapy studies, the only adverse drug reaction that was unequivocally related to treatment was dizziness (2.5% incidence on olmesartan medoxomil and 0.9% on placebo).

The incidence was also somewhat higher on olmesartan medoxomil compared with placebo for hypertriglyceridaemia (2.0% versus 1.1%) and for raised creatine phosphokinase (1.3% versus 0.7%).

Tabulated list of adverse reactions:

Adverse reactions from Olmesartan in clinical trials, post-authorisation safety studies and spontaneous reporting are summarized in the below table.

The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.

Additional information on special populations

Paediatric population

The safety of olmesartan medoxomil was monitored in 361 children and adolescents, aged 1-17 years old during 2 clinical trials. Whilst the nature and severity of the adverse events are similar to that of the adults, the frequency of the following is higher in the children:

- Epistaxis is a common adverse event in children (i.e. ≥ 1/100 to < 1/10) that has not been reported in adults.

- During the 3 weeks of double blind study, the incidence of treatment emergent dizziness and headache nearly doubled in children 6-17 years of age in the high olmesartan medoxomil dose group.

The overall safety profile for olmesartan medoxomil in paediatric patients does not differ significantly from the safety profile in adults.

Elderly (age 65 years or over)

In elderly people the frequency of hypotension is slightly increased from rare to uncommon.

To report any side effect(s):
• Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222,
Ext: 2317-2356-2353-2354-2334-2340.
Toll free phone:
8002490000 E-mail:
npc.drug@sfda.gov.sa
Website:
www.sfda.gov.sa/npc
• Other GCC States:
− Please contact the relevant competent authority.

Only limited information is available regarding overdosage in humans. The most likely effect of
overdosage is hypotension. In the event of overdosage, the patient should be carefully monitored and
treatment should be symptomatic and supportive.
No information is available regarding the dialysability of olmesartan.

Pharmacotherapeutic group: Angiotensin II antagonists, ATC code: C09CA08.
Mechanism of action / Pharmacodynamic effects
Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1)
antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor,
regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the
angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in
plasma aldosterone concentrations.
Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and
plays a significant role in the pathophysiology of hypertension via the type 1 (AT1) receptor.
Clinical efficacy and safety
In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial
blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during longterm
treatment, or of rebound hypertension after cessation of therapy.
Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood
pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood
pressure as twice daily dosing at the same total daily dose.
With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after
the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is
already observed after 2 weeks of treatment. When used together with hydrochlorothiazide, the
reduction in blood pressure is additive and coadministration is well tolerated.
The effect of olmesartan on mortality and morbidity is not yet known.
The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in
4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular
risk factor, investigated whether treatment with olmesartan could delay the onset of
microalbuminuria. During the median follow-up duration of 3.2 years, patients received either
olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.
For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of
microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction
was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8%
(210 of 2139) in the placebo group developed microalbuminuria.
For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and
in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with
olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar
rates for non- fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial infarction
(17 patients (0.8%)
vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients (0.5%) vs. 12 patients (0.5%)).
Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients
(0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.
The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial
(ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577
randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a
median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other
antihypertensive agents including ACE inhibitors.
The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage
renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129
patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite
secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53 placebotreated
patients (18.7%). This composite cardiovascular endpoint included cardiovascular death in 10
(3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall mortality 19 (6.7%)
versus 20
(7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7
(2.5%), respectively.
Paediatric population

The antihypertensive effects of olmesartan medoxomil in the paediatric population were evaluated in
a randomized, double-blind, placebo-controlled study in 302 hypertensive patients aged 6 to 17 years.
The study population consisted of an all black cohort of 112 patients and a mixed racial cohort of 190
patients, including 38 blacks. The etiology of the hypertension was predominantly essential
hypertension (87% of the black cohort and 67% of the mixed cohort). Patients who weighed 20 to <35
kg were randomized to 2.5 mg (low dose) or 20 mg (high dose) of olmesartan medoxomil once daily
and patients who weighed ≥35 kg were randomized to 5 mg (low dose) or 40 mg (high dose) of
olmesartan medoxomil once daily. Olmesartan medoxomil significantly reduced both systolic and
diastolic blood pressure in a weight-adjusted dose-dependent manner. Olmesartan medoxomil at both
low and high doses significantly reduced systolic blood pressure by 6.6 and 11.9 mmHg from the
baseline, respectively. This effect was also observed during the 2 weeks randomized withdrawal
phase, whereby both mean systolic and diastolic blood pressures demonstrated a statistically
significant rebound in the placebo group compared to olmesartan group. The treatment was effective
in both, paediatric patients with primary and secondary hypertension. As observed in adult
populations, the blood pressure reductions were smaller in black patients.
In the same study, 59 patients aged 1 to 5 years who weighed ≥5 kg received 0.3 mg/kg of olmesartan
medoxomil once daily for three weeks in an open label phase and then were randomized to receiving
olmesartan medoxomil or placebo in a double-blind phase. At the end of the second week of
withdrawal, the mean systolic/diastolic blood pressure at trough was 3/3 mmHg lower in the group
randomized to olmesartan medoxomil; this difference in blood pressure was not statistically
significant (95% C.I. -2 to 7/-1 to 7).
Other information:
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs
Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an
angiotensin II receptor blocker.

ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular
disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA
NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and
mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as
compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results
are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.
ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in
patients with diabetic nephropathy.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)
was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or
an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease,
cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse
outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group
than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia,
hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the
placebo group.

Absorption and distribution
Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite,
olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the
gastrointestinal tract.
No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma
or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.

The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2 hours after
oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase
approximately linearly with increasing single oral doses up to about 80 mg.
Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil
may be administered with or without food.
No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have
been observed.
Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant
protein binding displacement interactions between olmesartan and other highly bound coadministered
drugs is low (as confirmed by the lack of a clinically significant interaction between olmesartan
medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume
of distribution after intravenous dosing is low (16 – 29 L).
Biotransformation and elimination
Total plasma clearance was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic
blood flow (ca 90 L/h). Following a single oral dose of 14C-labelled olmesartan medoxomil, 10 - 16%
of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose
administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on
the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both
renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was
identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of
olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in
patients with biliary obstruction is contraindicated (see section 4.3).
The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral
dosing. Steady state was reached after the first few doses and no further accumulation was evident
after 14 days of repeated dosing. Renal clearance was approximately 0.5 – 0.7 L/h and was independent
of dose.
Pharmacokinetics in special populations
Paediatric population:
The pharmacokinetics of olmesartan was studied in paediatric hypertensive patients aged 1 to 16
years. The clearance of olmesartan in paediatric patients was similar to that in adult patients when
adjusted by the body weight.
There is no pharmacokinetic information available in renally impaired paediatric subjects.
Elderly (age 65 years or over):
In hypertensive patients, the AUC at steady state was increased by ca 35% in elderly people (65 – 75
years old) and by ca 44% in very elderly people (≥ 75 years old) compared with the younger age
group. This may be at least in part related to a mean decrease in renal function in this group of
patients.
Renal impairment:
In renally impaired patients, the AUC at steady state increased by 62%, 82% and 179% in patients
with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see
sections 4.2, 4.4).
Hepatic impairment:
After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and
moderately hepatically impaired patients, respectively, than in their corresponding matched healthy
controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with
mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and
0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment,
olmesartan mean AUC was again about 65% higher than in matched healthy controls. Olmesartan mean Cmax
values were similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been
evaluated in patients with severe hepatic impairment (see sections 4.2, 4.4).
Drug interactions
Bile acid sequestering agent colesevelam:
Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride
in healthy subjects resulted in 28% reduction in Cmax and 39% reduction in AUC of olmesartan. Lesser
effects, 4% and 15% reduction in Cmax and AUC respectively, were observed when olmesartan
medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half life of
olmesartan was reduced by 50 – 52% irrespectively of whether administered concomitantly or 4 hours
prior to colesevelam hydrochloride (see section 4.5).

In chronic toxicity studies in rats and dogs, olmesartan medoxomil showed similar effects to other
AT1 receptor antagonists and ACE inhibitors: raised blood urea (BUN) and creatinine (through
functional changes to the kidneys caused by blocking AT1receptors); reduction in heart weight; a
reduction of red cell parameters (erythrocytes, haemoglobin, haematocrit); histological indications of
renal damage (regenerative lesions of the renal epithelium, thickening of the basal membrane,
dilatation of the tubules). These adverse effects caused by the pharmacological action of olmesartan
medoxomil have also occurred in preclinical trials on other AT1 receptor antagonists and ACE
inhibitors and can be reduced by simultaneous oral administration of sodium chloride.
In both species, increased plasma renin activity and hypertrophy/hyperplasia of the juxtaglomerular
cells of the kidney were observed. These changes, which are a typical effect of the class of ACE
inhibitors and other AT1 receptor antagonists, would appear to have no clinical relevance.

Like other AT1 receptor antagonists olmesartan medoxomil was found to increase the incidence of
chromosome breaks in cell cultures in vitro. No relevant effects were observed in several in vivo
studies using olmesartan medoxomil at very high oral doses of up to 2000 mg/kg. The overall data of
a comprehensive genotoxicity testing suggest that olmesartan is very unlikely to exert genotoxic
effects under conditions of clinical use.
Olmesartan medoxomil was not carcinogenic, neither in rats in a 2 year study nor in mice when tested
in two 6 month carcinogenicity studies using transgenic models.
In reproductive studies in rats, olmesartan medoxomil did not affect fertility and there was no evidence
of a teratogenic effect. In common with other angiotensin II antagonists, survival of offspring was
reduced following exposure to olmesartan medoxomil and pelvic dilatation of the kidney was seen after
exposure of the dams in late pregnancy and lactation. In common with other antihypertensive agents,
olmesartan medoxomil was shown to be more toxic to pregnant rabbits than to pregnant rats, however,
there was no indication of a fetotoxic effect.

 Lactose Monohydrate
 Microcrystalline Cellulose PH 113
 Low Subs. Hydroxypropyl Cellulose LH 21
 Hydroxypropyl Cellulose
 Lactose Monohydrate (Supertab 11 SD)
 Magnesium Stearate
 Opadry 20A280019 White
 Purified Water

Not applicable

Do not store above 30°C

Film Coated Tablets, 28‘s Alu-Alu Blister

No special requirements